Cardiol Therapeutics Inc. (CRDL:TSX) closed at $1.47 on November 13, 2026, unchanged on the day. The stock trades 54.5% below its 52-week high of $3.23 and 20.0% above its 52-week low of $1.23. Over the past year, it gained 2.1%. Cardiol Therapeutics Inc. is part of the Health Care sector.
In 252 trading sessions since November 13, 2025, CRDL closed higher on 120 days (48%). Its best day was August 13, 2026 (+14.15%) and its worst was December 1, 2025 (-14.57%). The stock moved 10% or more in a single session 9 times.
Cardiol Therapeutics Inc. is a leader in the research and commercial development of pharmaceutical cannabidiol products and targeted therapies for heart failure and cancer. The Company is leveraging its expertise in pharmaceutical cannabinoids to develop proprietary formulations for three important medical markets: commercializing a line of greater than 99.5% purity pharmaceutically-manufactured cannabidiol products (with less than 10 ppm THC); developing nanotechnologies designed to deliver cannabinoids and other anti-inflammatory drugs for the treatment of heart failure; and pursuing an innovative cancer immunotherapeutic in combination with cannabinoids for treating Glioblastoma Multiforme. Cardiol brings together a wealth of research and development experience with advanced manufacturing capabilities, comprising business and thought leaders with extensive industry experience and expertise in commercializing proprietary drugs.
Find more stocks like CRDL with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.